Shanghai, China, 08 January 2024 – MicroPort EverPace recently announced the approval of the Genesis RMN™ Cardiac Electrophysiology Robotic Magnetic Navigation System (Genesis RMN™ System) by the National Medical Products Administration (NMPA) in China. Exclusively distributed by MicroPort EverPace , this system represents a major breakthrough in cardiac electrophysiology.
Developed by Stereotaxis, the FDA-approved and CE-certified Genesis RMN™ System leverages magnetic navigation technology for precise 3D catheter guidance. Low-intensity magnetic fields control the catheter tip with flexibility, reaching any heart chamber position. The system enables catheter configurations beyond traditional ablation techniques, accessing complex anatomical structure such as septal pathways and congenital anomalies. Its spatial memory ensures precise and repeatable mapping and ablation during challenging procedures, while remote operation enhances procedures precision and multi-location collaboration, broadening access to advanced care.
The Genesis RMN™ System features an innovative structural design that enhances speed, reduces size and weight, and improves operational flexibility, building upon the original RMN system. The Genesis RMN™ System utilizes smaller magnets that rotate along their center of mass, allowing for unprecedented responsiveness to physician control. Across a broad range of navigational routines, the System operates 70% to 80% faster than its predecessor. Additionally, the compact design increases space in the labs, providing a more efficient work environment for medical teams.
Stereotaxis, founded in 1990 and headquartered in Missouri, USA, is a global leader in robotic technologies for electrophysiology. Since launching the first magnetic navigation electrophysiology robot in 2003, Stereotaxis has advanced the system through five generations, establishing a universal robotic platform for vascular intervention.
In 2021, MicroPort EverPace entered a strategic partnership with Stereotaxis, becoming the exclusive distributor of its robotic magnetic navigation systems in China.
“We are delighted to receive NMPA clearance for the Genesis System in China,” said David Fischel, Chairman and CEO of Stereotaxis. “This approval represents another key milestone as we establish the foundations for significant growth across key focus geographies. Our investment to advance the substantial innovations underscores our commitment to pioneering the frontiers of medical technology to improve the lives of patients with cardiovascular disease around the world.”
“We are proud to partner with Stereotaxis to bring the benefits of the Genesis system to China,” said Dr. Sun Yiyong, President of MicroPort EverPace. “We look forward to launching this significant technology and continuing our partnership to provide China’s electrophysiology community with the most advanced innovations.”
About MicroPort EverPace
Founded in 2010, MicroPort EverPace (Shanghai MicroPort EP MedTech Co., Ltd; SSE: 688351), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical devices company focusing on the development, manufacturing, and commercializing minimally invasive medical devices for the treatment of cardiac arrhythmia. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These solutions are used by hundreds of physicians at over 1000 hospitals over more than 30 countries. MicroPort EverPace strives to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.everpace.com/en